MDT Medtronic plc
Trend channel, buy level and 3-month target. Information only, not financial advice.
Inside the channel · 9-month channel rising
Price is between the lines.
- 9-month channel
- US$88.78 – US$105.44 · rising, +5% a year
- Price in channel
- 47% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$105.44
- Turns bearish below
- US$88.78
Price history, with the path projected 3 months forward
Updated 7:09 AM ET (4 h ago)
- Daily close
- Upper trend line (9 months)
- Lower trend line (9 months)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
Hit rate too low on this symbol (1/5) — no published call or alerts; levels below are for reference.
Buy at or below
US$89.56
level as at 11 Nov 2026
Our target
US$96.72
by 2 Nov 2026
Projected move
8.0%
gross, before costs
Price is between our buy and target.
Target: MDT's usual move size (8.0%), the best return per day on this path.
5 settled calls · 1 reached target (20%) · average best move 5.1%. See the full record.
- Upper line touches
- 3
- Lower line touches
- 2
- Fit confidence
- 72%
- Fitted
- 1 Nov 2026
Company information
About Medtronic plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha
- Employees
- 95,000
- Country
- IE
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$113.46B
- Enterprise value
- —
- Beta
- 0.57
- Avg volume
- 9.19M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 73.31-106.33
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.